Home|Journals|Articles by Year

Directory for Medical Articles
 

Original Research



Dobesilate: A potential therapy for long-covid?

Pedro Cuevas, Antonio Manquillo, Javier Angulo, Guillermo Giménez-Gallego.


Abstract

On the basis of the involvement of fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) in inflammation and vascular changes in COVID-19, we hypothesized that Dobesilate, a demonstrated anti-FGF and anti-VEGF drug might be beneficial for treating COVID-19 patients. We conducted a study and recruited 13 patients with long-COVID syndrome from one center. Dobesilate (Doxium® 1g, twice a day for 15 days) shows clinical efficacy by improving symptoms in these patients.

Key words: SARS-CoV-2, COVID-19, Long-COVID, Dobesilate






Full-text options


Share this Article



Online Article Submission
• ejmanager.com







eJManager.com
Review(er)s Central
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.